II phase study

Overview of attention for article published in Frontiers in immunology, May 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 5 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 34,939 followers.

RT @FrontImmunol: New Research: Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concur…

02 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concur…

01 Jun 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concur…

01 Jun 2023

Reply Repost Favourite

New Research: Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study: Background Esophageal cancer (EC) is an aggressive neoplasm of… #immunology ht

01 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.